Tag: Primacor

As a phosphodiesterase-3 (PDE3) inhibitor, milrinone increases cardiac contractility and causes vasodilation, but its direct effect on heart rate can be complex and variable. This medication is typically used for the short-term treatment of acute decompensated heart failure, yet a significant increase in heart rate, including serious arrhythmias, remains a known risk.

Milrinone is a powerful medication used primarily in hospital settings for the short-term intravenous treatment of acute decompensated heart failure (ADHF). Its use is reserved for serious, often life-threatening, situations where other treatments have not been effective.

Clinical trials have shown that Primacor is not safe or effective for long-term use in heart failure patients, and prolonged therapy can significantly increase the risk of mortality. So, what is the use of Primacor? This powerful intravenous medication is strictly reserved for the short-term management of acute, severe decompensated heart failure and other critical cardiac conditions, exclusively in a hospital setting.

Milrinone is a powerful medication used primarily in intensive care and perioperative settings to manage severe, acute heart failure. Its classification as a phosphodiesterase-3 (PDE3) inhibitor allows it to increase the heart's pumping strength while simultaneously relaxing blood vessels.